Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 1, 2012, Pages 225-230

  Moreira Osório, Thaís ^a   Delle Monache, Franco ^b   Domeneghini Chiaradia, Louise ^a   Mascarello, Alessandra ^a   Regina Stumpf, Taisa ^a   Roberto Zanetti, Carlos ^a   Bardini Silveira, Douglas ^a   Regina Monte Barardi, Célia ^a   De Fatima Albino Smânia, Elza ^a   Viancelli, Aline ^a   Ariel Totaro Garcia, Lucas ^a   Augusto Yunes, Rosendo ^a   José Nunes, Ricardo ^a   Smânia Jr , Artur ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antibacterial activity; Chalcones; Cytotoxic activity; Hydrazones; MRSA; Oxadiazoles; PCR and RAPD

Indexed keywords

2',4 DIHYDROXY 3',4' (2,2, DIMETHYL 3,4 DIHYDROPYRANYL)CHALCONE(4 HYDROXY LONCHOCARPIN); 2',4',4 TRIHYDROXY 3' PRENYL CHALCONE(4 HYDROXY ISOCORDOIN); 2',4,4' TRIHYDROXY 3' GERANYL 3 PRENYL CHALCONE; 2',4,4' TRIHYDROXY 3' GERANYL CHALCONE; 2',4,4',6' TETRAHYDROXY DIHYDROCHALCONE; 2,2',4' TRIHYDROXY CHALCONE; ANTIBIOTIC AGENT; CEFOXITIN; CHALCONE DERIVATIVE; HYDRAZONE DERIVATIVE; OXADIAZOLE DERIVATIVE; PENICILLIN BINDING PROTEIN 2A; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIOSTASIS; DRUG CYTOTOXICITY; DRUG SAFETY; DRUG SCREENING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CERCOPITHECUS AETHIOPS; CHALCONES; HUMANS; HYDRAZONES; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, CHEMICAL; OXADIAZOLES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VERO CELLS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 84655169698     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.11.059     Document Type: Article

References (53)

1. C. Walsh Antibiotics: actions origins resistance 2003 SM Press Washington
2. M.C. Maranan, B. Moreira, S. Boyle-Vavra, and R.S. Daum Infect Dis. Clin. North Am. 11 1997 813
3. A.M. Vivone, and B.M. Moreira Memórias do Instituto Oswaldo Cruz 100 2005 693
4. H.F. Chambers, and F.R. Deleo Nature Rev. 7 2009 629
5. D.C. Oliveira, A. Tomasz, and H. de Lencastre Lancet Infect. Dis. 2 2002 180
6. M.E. Velázquez-Meza Salud Pública de México 47 2005 381
7. R. Wise J. Antim. Chemotherapy 51 2003 ii5
8. R. Veronesi, and R. Focaccia Tratado de Infectologia 2nd ed. 2004 Atheneu São Paulo
9. P. Moreillon Clin. Microbiol. Infect. 14 2008 32
10. P.M. Dewick Medicinal Natural Products: A Biosinthetic Approach 1997 John Wiley & Sons Cichestes Chapter 4
11. S.J. Won, and C.T. Liu Eur. J. Med. Chem. 40 2005 103
12. Z.A. Nowakowska Eur. J. Med. Chem. 42 2007 125
13. L. Ni, C.Q. Meng, and J.A. Sikorski Expert Opin. Ther. Pat. 14 2004 1669
14. K. Okada, Y. Takamura, M. Yamamoto, Y. Inoue, R. Takagaki, K. Takahashi, S. Demizu, K. Kajiyama, Y. Hiraga, and T. Kinoshita Chem. Pharm. Bull. 37 1989 2528
15. S. Rollas, and S.G. Küükgüzel Molecules 12 2007 1910
16. D.M. Borchhardt, A. Mascarello, L.D. Chiaradia, R.J. Nunes, G. Oliva, R.A. Yunes, and A.D. Andricopulo J. Braz. Chem. Soc. 21 2010 142
17. L. Jin, J. Chen, B. Song, Z. Chen, S. Yang, Q. Li, D. Hu, and R. Xu Bioorg. Med. Chem. 16 2006 5036
18. M. Grinholc, A. Kawiak, J. Kurlenda, A. Graczyk, and K.P. Bielawski Acta Biochim. Pol. 55 2008 85
19. H.P. Ávila, E.F.A. Smânia, F. Delle Monache, and A. Smânia Júnior Bioorg. Med. Chem. 16 2008 9790
20. L.D. Chiaradia, R. dos Santos, C.E. Vitor, A.A. Vieira, P.C. Leal, R.J. Nunes, J.B. Calixto, and R.A. Yunes Bioorg. Med. Chem. 16 2008 658
21. S. Tsai, and J.P. Klinmam Bioorg. Chem. 31 2003 172
22. T. Högberg, S. Bengtsson, T.De. Paulis, L. Johansson, P. Ström, H. Hall, and S.O. Ögren J. Med. Chem. 33 1990 1155
23. C. Pérez-Melero, A.B.S. Maya, B. del Rey, R. Peláez, E. Caballero, and M. Medarde Bioorg. Med. Chem. Lett. 14 2004 3771
24. L. Jin, J. Chen, B. Song, Z. Chen, S. Yang, Q. Li, D. Hu, and R. Xu Bioorg. Med. Chem. Lett. 16 2006 5036
25. A.S. Chida, P.V.S.N. Vani, M. Chandrasekharam, R. Srinivasan, and A.K. Singh Synth. Commun. 31 2001 657
26. P.K. Dubey, S.S. Rao, and P.V.P. Reddy Heterocycl. Commun. 9 2003 411
27. M.A. Khalil, O.A. El-Sayed, and H.A. El-Shamy Arch. Pharm. 326 1993 489
28. M.J. Hearn, and P.-Y. Chanyaputhipong J. Heterocycl. Chem. 32 1995 1647
29. S.K. Lee, U.K. Tambar, N.R. Perl, and J.L. Leighton Tetrahedron 66 2010 4769
30. D.G. Rando, M.A. Avery, B.L. Tekwani, S.I. Khan, and E.I. Ferreira Bioorg. Med. Chem. 16 2008 6724
31. R. Frimm, S. Kovac, J. Kovac, and K. Bencze Chemicke Zvesti 22 1968 447
32. L. Wen, H. Yin, W. Li, and K. Li Acta Crystallogr., Sect. E 65 2009 o2623
33. P.C. Lima, L.M. Lima, K.C.M. Da Silva, P.H.O. Leda, A.L.P. De Miranda, C.A.M. Fraga, and E.J. Barreiro Eur. J. Med. Chem. 35 2000 187
34. The bioactive compounds and the vancomycin were tested against the MRSA using the microdilution broth method. More information in Supplementary data.
35. M.V. Souza, C. Reis, and F.C. Pimenta Revista de Patologia Tropical 34 2005 27
36. Isolates with zone diameter ≤19 mm were reported as resistant and ≥23 mm were considered as sensitive to oxacillin. For cefoxitin, an inhibition zone diameter ≤21 mm was reported as resistant and ≥22 mm was considered sensitive.
37. Genomic DNA was extracted from all bacterial cultures using the phenol/chloroform method, and used as template for PCR amplification. More information in Supplementary data.
38. K. Oberdorfer, S. Pohl, M. Frey, K. Heeg, and C. Wendt Eur. J. Clin. Microbiol. Infect. Dis. 25 2006 657
39. W.V. Leeuwen, M. Sijmons, J. Sluijs, H. Verbrugh, and A.V. Belkum J. Clin. Microbiol. 34 1996 2770 more information in Supplementary data
40. J.M. Swenson, D. Lonsway, S. McAllister, A. Thompson, L. Jevitt, and J.B. Patel Diagnostic Microbiol. Infect. Dis. 58 2007 33
41. K.B. Anand, P. Agrawal, S. Kumar, and K. Kapila Ind. J. Med. Microbiol. 27 2009 27
42. Bertoluci, D. F. F. Master thesis. São Paulo University, Pharmaceutical Sciences Departament, 2007. Available from: http://www.teses.usp. br/teses/disponiveis/9/9139/tde-13092007-100702/pt-br.php.
43. L.C. Tavares, J.J. Chiste, M.G.B. Santos, and T.C.V. Penna Bull. Chim. Farm. 138 1999 432
44. S. Rollas, N. Gülerman, and H. Erdeniz Il Farmaco 57 2002 171
45. A. Masunari, and L.C. Tavares Bioorg. Med. Chem. 15 2007 4229
46. M. Sato, H. Tanaka, R. Yamaguchi, T. Oh-Uchi, and H. Etoh Lett. Appl. Microbiol. 37 2003 81
47. M. Alvarez, E.P. Zarelli, N.B. Pappano, and N.B. Debattista Biocell 28 2004 31
48. Devia, C. M.; Pappano, N. B.; Debattista, N. B. Rev. Microbiol. 1998, 29. Available from http://dx.doi.org/10.1590/S0001-37141998000400014
49. S.F. Nielsen, T. Boesen, M. Larsen, K. Schønning, and H. Kromann Bioorg. Med. Chem. 12 2004 3047
50. For the minimal bactericidal concentration (MBC) assay, aliquots (10 μL) of each culture without visible growth were spread on blood agar plates. The MBC was the lowest concentration of the compounds that inhibited completely the bacterial growth.
51. The cytotoxicity of the compounds was evaluated with a colorimetric assay as described by Mosmann with the modifications suggested by Andrighetti-Fröhner and col. T. Mosmann J. Immunol. Methods 65 1983 55
52. C.R. Andrighetti-Fröhner, R.V. Antonio, T.B. Creczynski-Pasa, C.R.M. Barardi, and C.M.O. Simões Memórias do Instituto Oswaldo Cruz 98 2003 843 more information in Supplementary data
53. J.R. Dimmock, N.M. Kandepu, M. Hetherington, J.W. Quail, U. Pugazhenthi, A.M. Sudom, M. Chamankhah, P. Rose, E. Pass, T.M. Allen, S. Halleran, J. Szydlowski, M. Mutus, M. Tannous, E.K. Manavathu, T.G. Myers, E. De Clercq, and J. Balzarini J. Med. Chem. 26 1998 1014